Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial.

Subgroup analysis of children (5-12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders. The primary efficacy measure was the Aberrant Behavior Checklist-Irritability (ABC-I) subscale. Data were available for 55 children given risperidone (n=27) or placebo (n=28); mean baseline ABC-I ( +/- SD) was 20.6 (8.1) and 21.6 (10.2). Risperidone [mean dose ( +/- SD): 1.37 mg/day (0.7)] resulted in significantly greater reduction from baseline to endpoint in ABC-I versus placebo [mean change ( +/- SD): -13.4 (1.5) vs. -7.2 (1.4), P<0.05; ES=-0.7]. The most common adverse effect with risperidone was somnolence (74% vs. 7% with placebo). Risperidone treatment was well tolerated and significantly improved behavioral problems associated with autism.
AuthorsGahan J Pandina, Cynthia A Bossie, Eriene Youssef, Young Zhu, Fiona Dunbar
JournalJournal of autism and developmental disorders (J Autism Dev Disord) Vol. 37 Issue 2 Pg. 367-73 (Feb 2007) ISSN: 0162-3257 [Print] United States
PMID17019624 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Antipsychotic Agents
  • Risperidone
  • Antipsychotic Agents (therapeutic use)
  • Autistic Disorder (epidemiology)
  • Child
  • Child, Preschool
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Mood Disorders (drug therapy, epidemiology)
  • Psychomotor Disorders (drug therapy, epidemiology)
  • Risperidone (therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: